Agilent Technologies Grows Life Sciences Business With Strategic Acquisition; Terms Not Disclosed
Agilent Technologies Inc. (NYSE: A) today announced it is expanding its life sciences business with two strategic acquisitions. Halo Genomics, a provider of innovative technology for the rapidly growing next-generation DNA sequencing market, has now joined Agilent. In addition, Agilent has signed a definitive acquisition agreement with BioSystem Development, a company that creates and manufactures solutions to meet the analytical needs of the life sciences industry.
Both companies are privately held. Financial details were not disclosed.
“Life science is the growth engine for Agilent, and these acquisitions are strategically very important,” said Nick Roelofs, president of Agilent's Life Sciences Group. “We're getting world-class technology and expertise in two key areas that will help us expand our portfolio and deliver the most complete workflow solutions for our customers.”
The acquisition of Halo, based in Uppsala, Sweden, is now final. The asset acquisition of BioSystem Development, headquartered in Madison, Wis., is expected to be completed by the end of the calendar year, subject to customary closing conditions.
